A Multi-Omics Study of Vasospastic Angina
KIVAM
Identification of the Key Factors Increasing the Risk of Vasospastic Angina Based on Multi-omics.
1 other identifier
observational
1,200
1 country
1
Brief Summary
This is a observational study to identify the key factor associated with vasospastic angina and to explore the prognosis of the participants. The study will recruit 400 patients with vasospastic angina, 400 healthy controls and 400 patients with acute myocardial infarction. Next generation sequencing, metabolome and proteomics will be performed in these participants.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2012
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2012
CompletedFirst Submitted
Initial submission to the registry
March 7, 2022
CompletedFirst Posted
Study publicly available on registry
March 16, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2022
CompletedMarch 16, 2022
March 1, 2022
10.9 years
March 7, 2022
March 7, 2022
Conditions
Outcome Measures
Primary Outcomes (3)
Cardiovascular Death
Death from cardiovascular causes and any unknown death unless there was another certain cause
up to 48 months
Stroke
A rapid onset of a new focal loss of neurologic function caused by an ischemic central nervous system event with residual symptoms lasting at least 24 hours from their onset or leading to death
up to 48 months
Myocardial Infarction
The definition of myocardial infarction was consistent with the Third Universal Definition of Myocardial Infarction.
up to 48 months
Secondary Outcomes (2)
Recurrent angina
up to 48 months
Rehospitalization due to cardiovascular causes
up to 48 months
Study Arms (3)
Patients with acute myocardial infarction
Patients with acute myocardial infarction
Healthy controls
Healthy controls
Patients with vasospastic angina
Patients with vasospastic angina
Eligibility Criteria
Chinese patients with vasospastic angina
You may qualify if:
- years of age or older
- diagnosed as vasospastic angina
You may not qualify if:
- participate in any drug clinical trials within 3 months
- patients with life-threatening complications, or the researchers determined that the survival time of patients with no more than 1 years
- serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients)
- previous history of cancer or tumor, or pathological examination confirmed precancerous lesions (such as breast ductal carcinoma in situ, or atypical hyperplasia of the cervix)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Tongji Hospitallead
Study Sites (1)
Tongji Hospital
Wuhan, Hubei, 430030, China
Biospecimen
Serum, Blood Cells and DNA
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof
Study Record Dates
First Submitted
March 7, 2022
First Posted
March 16, 2022
Study Start
January 1, 2012
Primary Completion
December 1, 2022
Study Completion
December 1, 2022
Last Updated
March 16, 2022
Record last verified: 2022-03